Australian scientists develop a nasal spray that can prevent SARS-CoV-2 infection


As coronovirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to wreak havoc globally, scientists race to develop an effective drug or vaccine to fight infection is. With more than 33.5 million people infected since the pandemic began in December 2019, finding treatment for those infected is important to reduce their prevalence.

Now, Ana Respiratory, a biotech company in Australia, said it is developing a nasal spray that can help boost the human immune system to fight the flu and the common cold, in a recent study in animals Has significantly reduced the development of coronovirus.

Potential nasal spray can not only help in the treatment of COVID-19, but can also prevent it.

Nasal spray

The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it has reduced viral replication by up to 96 percent in animal studies. The new study is described in a new study by Professor Miles Carroll, Deputy Director of Public Health England (PHE) and published in the open-source preprint server bioRxiv*.

Used as a nasal spray, it aims to boost the body’s natural immune system to fight the common cold and flu. It works by triggering the innate immune system, which is the body’s first line against infection with a pathogen. When the drug has enhanced the immune system, it also prevents infection and replication of SARS-CoV-2 in the laboratory.

Clinical observation. (A) Schematic of experimental design. Ferrets received INNA-051 and PBS treatment 4 days and 1 day prior to challenge with 5.0 x 106 pfu / ml SARS-CoV-2. Nasal washings and throat swabs were collected on days 1, 3, 5, 7, 10 and 12 post challenge (PC) for all treatment groups and the control group. Scheduled for 6/24 ferrets at 3/6 a day and measured twice (approximately 8 hours apart) at 12–14 pc (b) temperatures, using implanted temperature / ID chips. The standard error of the mean temperature +/- mean (SEM) is displayed. Temperature Dip SARS-CoV-2 Challenge

Was attributed to unconsciousness. (B) Plot daily and percent changes before treatment were recorded by ferret weight. Average percentage weight changes are displayed +/- SEM.

Clinical observation. (A) Schematic of experimental design. Ferrets received INNA-051 and PBS treatment 4 days and 1 day prior to challenge with 5.0 x 106 pfu / ml SARS-CoV-2. Nasal washings and throat swabs were collected on days 1, 3, 5, 7, 10 and 12 post challenge (PC) for all treatment groups and the control group. Scheduled for 6/24 ferrets at 3/6 a day and measured twice (approximately 8 hours apart) at 12–14 pc (b) temperatures, using implanted temperature / ID chips. The standard error of the mean temperature +/- mean (SEM) is displayed. Temperature Dip SARS-CoV-2 Challenge

Was attributed to unconsciousness. (B) Plot daily and percent changes before treatment were recorded by ferret weight. Average percentage weight changes are displayed +/- SEM.

the study

Respiratory system diseases, including the flu, common cold, and coronavirus infection, represent major global health hazards. These viruses have caused epidemics that are endangering the lives of people, such as children, older adults, and those who are immunocopromised, at higher risk.

SARS-CoV-2 infection is actively spreading worldwide, and it spreads quickly from one person to another through close contact and respiratory droplets. One of the greatest threats of the current pandemic is that many people infected with the virus are asymptomatic, meaning they do not know that they carry the virus. As a result, they are called silent broadcasters.

The research team of the National Infection Service, Public Health England (PHE) wanted to develop a nasal spray to prevent replication of the virus in the nasal area, which is the most common point of entry of the virus.
To test nasal spray, the team obtained samples of nasal washings and throat swabs four days before the viral challenge. Upon analyzing viral RNA in nasal wash samples, the team confirmed infection in all treatment groups, with lower viral RNA levels seen in INNA-051 treatment.

The team has found that prophylactic intra-nasal administration of INNA-051 in the SARS-CoV-2 ferret infection model reduces nasal and endangered viral RNA levels.

The team wrote in the paper, “Results of our study clinical development of a therapy based on prophylactic TLR2 / 6 innate immune activation in URT to reduce SARS-CoV-2 transmission and provide protection against COVID-19″ Support. ”

In addition, the research team stated that the prophylactic approach is important in people at high risk of developing community transmission or severe disease from COFID-19, such as older adults, people with comorbidity, and those who are immunologists.

He said, “We are surprised at how effective our treatment has been. By increasing the natural immune response of ferrets with our treatment, we have seen rapid eradication of the virus, ”said Christoph Damison, managing director of Ana Respiratory.

“If humans react in a similar way, the benefits of treatment are two-fold. Individuals exposed to the virus will most likely eradicate it rapidly, with treatment to ensure that the disease does not progress beyond mild symptoms. This is particularly relevant for vulnerable members of the community. Furthermore, the rapidity of this response means that infected individuals are unlikely to pass on it, which means a faster stop for community broadcasting, ”he said.

https://www.youtube.com/watch?v=AVkjoDG1ZVg

* Important Information

bioRxiv

    Publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be considered as conclusive, guiding clinical practice / health-related behavior or as established information.